NBP · ISSUER CIK 1778016
NovaBridge Biosciences
Between Aug 1, 2026 and Oct 29, 2026, 5 NovaBridge Biosciences insiders reported $0.00 of open-market purchases and $88K of sales on SEC Form 4.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 3 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$88KInsider selling
−$88KNet open-market
Oct 19, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 202616:15 | Oct 15, 2026 | NBP | Director | M · Exercise | — | +13,271 | 13,271 | New | — | ||
| Sep 21, 202616:05 | Sep 18, 2026 | NBP | Chief Medical Officer | S · Sell | $0.71 | −8,209 | 173,427 | -5% | −$6K | ||
| Sep 21, 202616:05 | Sep 17, 2026 | NBP | Chief Medical Officer | M · Exercise | — | +23,695 | 181,636 | +15% | — | ||
| Sep 11, 202616:30 | Sep 9, 2026 | NBP | Chief Bus. Development Officer | S · Sell | $0.74 | −107,978 | 266,467 | -29% | −$80K | ||
| Sep 8, 202617:51 | Sep 3, 2026 | NBP | Chief Bus. Development Officer | M · ExerciseLate 5d | — | +339,372 | 374,445 | +968% | — | ||
| Sep 1, 202618:00 | Aug 31, 2026 | NBP | EVP, Clinical Development | S · Sell | $0.79 | −3,282 | 304,201 | -1% | −$3K | ||
| Sep 1, 202618:00 | Aug 30, 2026 | NBP | EVP, Clinical Development | M · Exercise | — | +9,382 | 307,483 | +3% | — | ||
| Aug 25, 202616:15 | Aug 22, 2026 | NBP | Director | M · Exercise | — | +17,218 | 17,218 | New | — |